SCHEMBL3428987

SCHEMBL3428987

Clc1nc(N2CCOCC2)c2nnn(CCN3CCCCC3)c2n1

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.45
KDM4E B2RXH2 3/20 0.45
HRH3 Q9Y5N1 2/20 0.45
GAA P10253 1/20 0.45
HPGD P15428 3/20 0.43
CYP3A4 P08684 2/20 0.43
HSD17B10 Q99714 2/20 0.43
CNR2 P34972 5/20 0.42
TSHR P16473 1/20 0.41
LMNA P02545 2/20 0.40
ALOX15 P16050 1/20 0.40
HDAC1 Q13547 1/20 0.38
PIK3CA P42336 5/20 0.37
MTOR P42345 5/20 0.37
PIK3CG P48736 5/20 0.37
RECQL P46063 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3429949 0.93 ALDH1A1 (0.44) ALDH1A1KDM4EHRH3GAAHPGD
SCHEMBL3427707 0.83 PIK3CA (0.50) ALDH1A1KDM4EGAACNR2PIK3CA
SCHEMBL3428738 0.80 ALDH1A1 (0.45) ALDH1A1KDM4EGAAHPGDHSD17B10
SCHEMBL3430205 0.80 ALDH1A1 (0.45) ALDH1A1KDM4EGAAHPGDHSD17B10
SCHEMBL4535825 0.79 ALDH1A1 (0.45) ALDH1A1KDM4EGAACNR2HDAC1
SCHEMBL3408168 0.79 PIK3CA (0.44) ALDH1A1KDM4EHRH3GAAHPGD
SCHEMBL3430832 0.78 USP2 (0.42) ALDH1A1KDM4EGAAHDAC1PIK3CA
SCHEMBL4440568 0.78 HRH3 (0.53) ALDH1A1KDM4EHRH3HPGDCYP3A4
SCHEMBL3992479 0.78 SIGMAR1 (0.56) HRH3GAA
SCHEMBL3429479 0.77 ALDH1A1 (0.43) ALDH1A1KDM4EGAACNR2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2252296-A1 3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES Wyeth LLC (US) 2010-11-24 EP disclosed
WO-2009091788-A1 3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES WYETH (US) 2009-07-23 WO disclosed
US-20090181963-A1 3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES WYETH (US) 2009-07-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090181963-A1 3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES MTOR, PIK3CA, PIK3CD ALDH1A1 3181/4885KDM4E 1194/4885HRH3 1593/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.